Tigan (trimethobenzamide HCl)
Antiemetic Intramuscular Vial (ML)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Trimethobenzamide hydrochloride, which is structurally related to ethanolamine-derivative antihistamines, is an antiemetic.
Trimethobenzamide is used for the control of nausea and vomiting, including the treatment of postoperative nausea and vomiting, and also is used for the treatment of nausea associated with gastroenteritis. The drug is less effective as an antiemetic than phenothiazines, but may be associated with fewer adverse effects than phenothiazine therapy. When vomiting is severe and potentially hazardous and may likely be of short duration, phenothiazine antiemetics may be preferred.
When long-term antiemetic therapy is anticipated, non-phenothiazine antiemetics such as trimethobenzamide hydrochloride should be considered. The cause of vomiting should be established, if possible, and primary emphasis should be directed toward restoration of body fluids and electrolyte balance, relief of fever, and treatment of the causative disease process. Overhydration should be avoided since it may result in cerebral edema.
Generic name: trimethobenzamide HCl
Pronunciation: (trye-METH-oh-BEN-za-mide)
Drug class: Antiemetic
Therapeutic class: Gastrointestinal Therapy Agents
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Tigan
Indications
The following indications are listed for Tigan:
- Nausea
- Post-Operative Nausea And Vomiting
Also known as: Post Op Nausea And Vomiting, Postoperative Nausea And Vomiting, Queasy.
Dosing
For the control of nausea and vomiting, the usual adult oral dosage of trimethobenzamide hydrochloride is 300 mg 3 or 4 times daily. For the treatment of postoperative nausea and vomiting or for the treatment of nausea associated with gastroenteritis, the usual adult oral dosage of trimethobenzamide hydrochloride is 300 mg 3 or 4 times daily. In children weighing 13.6-45 kg, an oral dosage of 100 or 200 mg 3 or 4 times daily has been recommended; however, suitable oral dosage forms are no longer commercially available in the US. Dosage should be adjusted according to indication for use, severity of symptoms, and patient response.
The usual adult IM dosage is 200 mg 3 or 4 times daily. Dosage should be adjusted according to indication for use, severity of symptoms, and patient response.
Trimethobenzamide hydrochloride is administered orally or by IM injection. The drug is not recommended for IV administration. The preparation for rectal administration is no longer commercially available in the US; the US Food and Drug Administration (FDA) has withdrawn approval of the new drug application (NDA) for the rectal suppositories because of lack of substantial evidence of efficacy. (See Preparations.)
Local adverse effects associated with IM administration of trimethobenzamide hydrochloride may be minimized by injecting the drug deep into the upper outer quadrant of the gluteus maximus and avoiding local infiltration of the solution along the needle track.
| Drug label | Dosing type | Instructions |
|---|---|---|
| Tigan 100 Mg/Ml Vial | Maintenance | Inject 2 milliliters (200 mg) by intramuscular route 3 times per day as needed. |
| Drug label | Dosing type | Instructions |
|---|---|---|
| Trimethobenzamide 200 Mg/2 Ml | Maintenance | Inject 2 milliliters (200 mg) by intramuscular route 3 times per day as needed. |
Drug interactions
There is no enhanced messaging for this drug.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
There is no enhanced messaging for this drug.
There are no contraindication contraindications for this drug.
- Alcohol intoxication
- Chronic kidney disease stage 2 (mild) GFR 60-89 ml/min
- Chronic kidney disease stage 3A (moderate) GFR 45-59 ml/min
- Chronic kidney disease stage 3B (moderate) GFR 30-44 ml/min
- Chronic kidney disease stage 4 (severe) GFR 15-29 ml/min
- Chronic kidney disease stage 5 (failure) GFr<15 ml/min
- Disease of liver
- Dehydration
- Encephalitis
- High fever >101 degrees fahrenheit
- Kidney disease with likely reduction in glomerular filtration rate (GFr)
Adverse reactions
There is no enhanced messaging for this drug.
Less Frequent
- Opisthotonus
Rare or Very Rare
- Acquired dystonia
- Allergic dermatitis
- Angioedema
- Blood dyscrasias
- Coma
- Depression
- Extrapyramidal disease
- Jaundice
- Parkinsonism
- Seizure disorder
- Skin rash
More Frequent
- Drowsy
Less Frequent
- Blurred vision
- Cramps
- Diarrhea
- Dizziness
- Headache disorder
Rare or Very Rare
- Acute cognitive impairment
Precautions
No enhanced messaging available.
No enhanced messaging available.
Reproduction studies in rats and rabbits using trimethobenzamide dosages up to 100 mg/kg have not revealed evidence of teratogenicity; however, there was an increased incidence of fetal resorption and stillbirths in these animals. There are no adequate and controlled studies to date using trimethobenzamide in pregnant women, and safety of the drug during pregnancy has not been established.
Safety of trimethobenzamide in nursing women has not been established.
No enhanced messaging available.
ICD codes
| Code | Type | Description |
|---|---|---|
| Nausea | ||
| R11 | ICD10CM | Nausea and vomiting |
| R11.0 | ICD10CM | Nausea |
| R11.2 | ICD10CM | Nausea with vomiting, unspecified |
| Post-operative nausea and vomiting | ||
| K91.0 | ICD10CM | Vomiting following gastrointestinal surgery |
| R11.2 | ICD10CM | Nausea with vomiting, unspecified |
ICD code information from First Databank (FDB).
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.